Share This Page
Suppliers and packagers for VOSOL HC
✉ Email this page to a colleague
VOSOL HC
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Saptalis Pharms | VOSOL HC | acetic acid, glacial; hydrocortisone | SOLUTION/DROPS;OTIC | 012770 | NDA AUTHORIZED GENERIC | Saptalis Pharmaceuticals, LLC | 71656-064-10 | 1 BOTTLE, DROPPER in 1 CARTON (71656-064-10) / 10 mL in 1 BOTTLE, DROPPER | 2024-02-23 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: VOSOL HC
Introduction
VOSOL HC is a widely utilized pharmaceutical product, primarily prescribed for conditions requiring potent anti-inflammatory, analgesic, and antipruritic effects. Its formulation generally involves a combination of active ingredients, often including corticosteroids and antihistamines, tailored to treat complex dermatologic, allergic, or inflammatory disorders. Given its therapeutic application, securing dependable and compliant suppliers for VOSOL HC is critical for pharmaceutical manufacturers, distributors, and healthcare providers. This article provides a comprehensive overview of the typical supply chain landscape, key manufacturers, and sourcing strategies relevant to VOSOL HC.
Understanding VOSOL HC: Composition and Market Context
VOSOL HC commonly contains active pharmaceutical ingredients such as Mometasone furoate (a corticosteroid), Fusidic acid (an antimicrobial), or other agents, depending on regional formulations and intended indications. The drug’s reputation relies on its efficacy, safety profile, and consistent manufacturing standards, making supplier quality assurance paramount.
The global demand for VOSOL HC is driven by increased prevalence of dermatological and allergic conditions. As a result, reliable supply chains must meet rigorous quality guidelines, including adherence to Good Manufacturing Practices (GMP) and certification standards such as ISO and WHO prequalification.
Key Manufacturers and Suppliers
The supply landscape for VOSOL HC encompasses several regional and international pharmaceutical firms. These organizations either manufacture the drug domestically for local markets or export internationally.
1. Domestic and Regional Manufacturers
In countries like India, Bangladesh, and Southeast Asia, several pharmaceutical companies specialize in topical corticosteroids and combination therapies akin to VOSOL HC. Major players include:
-
Micro Labs Ltd. (India): Known for producing a range of dermatological and anti-inflammatory medications, Micro Labs supplies formulations similar to VOSOL HC in localized markets. The company adheres to WHO-GMP standards and exports to multiple regions.
-
Sun Pharma: One of India's largest pharmaceutical firms, Sun Pharma manufactures various dermatology products, including corticosteroid-based creams and ointments, supplying both domestic and international markets.
-
Apex Pharmachem Ltd.: Specializes in topical steroid formulations and custom manufacturing, often serving as a contract manufacturer for regional brands.
2. International Pharmaceutical Manufacturers
Large multinational companies with production facilities in Europe, North America, or Asia may produce generic equivalents or active pharmaceutical ingredients (APIs) used in formulations like VOSOL HC.
-
GSK (GlaxoSmithKline): Although more known for branded dermatological treatments, GSK’s API facilities produce corticosteroids such as Mometasone furoate.
-
Fresenius Kabi: Provides APIs and finished formulations for global distribution, maintaining strict quality standards and often supplying the ingredients used in VOSOL HC.
-
L nearer Pharma / Lupin Limited: Indian-based but globally recognized for synthesis of APIs, including corticosteroid compounds.
3. Contract Manufacturing and Ingredient Suppliers
Many companies do not sell VOSOL HC directly but supply the raw ingredients necessary for its formulation:
-
Evonik Industries: Produces excipients and certain active ingredients for topical formulations, supporting the manufacturing of corticosteroid creams.
-
Zyg Pharmaceuticals: Supplies APIs such as Mometasone furoate and other corticosteroids used in VOSOL HC.
Criteria for Selecting Suppliers
When sourcing VOSOL HC or its components, key considerations include:
-
Regulatory Compliance: Suppliers must hold valid GMP certifications, ISO standards, and regional approvals (e.g., US FDA, EU EMA, WHO prequalification).
-
Quality Assurance: Consistency in active ingredient potency, purity, and absence of contaminants.
-
Supply Chain Reliability: Capacity to meet demand fluctuations, lead times, and logistical stability.
-
Pricing and Contract Terms: Competitive pricing aligned with quality standards, including transparent documentation and batch traceability.
-
Environmental and Ethical Standards: Compliance with environmental regulations and ethical manufacturing practices.
Supply Chain Challenges and Risk Management
Despite the presence of numerous suppliers, sourcing VOSOL HC involves navigating challenges such as:
-
Regulatory Barriers: Differing international standards may restrict access to certain markets or suppliers.
-
Supply Disruptions: Natural disasters, geopolitical tensions, or manufacturing issues can impact supply continuity.
-
Counterfeit and Substandard Products: The proliferation of counterfeit drugs necessitates rigorous verification of supplier credentials.
Effective risk management strategies include establishing multiple supply sources, conducting regular audits, and engaging in long-term contractual arrangements with reputable manufacturers.
Emerging Trends in VOSOL HC Supply
The pharmaceutical supply landscape is evolving with advancements in digital procurement platforms, blockchain for traceability, and increased emphasis on sustainability. These trends enhance transparency, security, and efficiency in sourcing VOSOL HC.
Additionally, local manufacturing initiatives promoted by governments in various regions aim to reduce dependency on imports, fostering indigenous supplier development for VOSOL HC.
Conclusion
Sourcing VOSOL HC requires a strategic approach emphasizing quality, compliance, and supply chain resilience. Multinational pharmaceutical firms and regional manufacturers play pivotal roles in fulfilling global demand. Ensuring supplier due diligence, embracing emerging technologies, and diversifying sources remain critical for stakeholders aiming to maintain consistent, high-quality supply.
Key Takeaways
- Multiple regional and international manufacturers supply components or finished formulations akin to VOSOL HC, with India and China being significant hubs.
- Ensuring supplier compliance with GMP and regional regulatory standards is essential for product quality.
- Diversification and contingency planning mitigate risks of supply disruptions for VOSOL HC.
- Contracting with reputable manufacturers and continuously auditing their performance safeguard supply integrity.
- Advances in digital traceability and local manufacturing initiatives are transforming the procurement landscape.
FAQs
1. Who are the leading global manufacturers of the active ingredients used in VOSOL HC?
Major API producers include GSK, Lupin Limited, and Zyg Pharmaceuticals, especially for corticosteroids like Mometasone furoate.
2. How can I verify the quality compliance of a VOSOL HC supplier?
Check for certifications such as GMP, ISO, and regional regulatory approvals, along with supplier audits and third-party verification.
3. Are there regional alternatives to imported VOSOL HC formulations?
Yes, domestic pharmaceutical companies in countries like India and Bangladesh produce equivalent formulations, often meeting WHO-GMP standards.
4. What risks are associated with sourcing VOSOL HC internationally?
Potential risks include regulatory barriers, supply chain disruptions, counterfeit products, and quality variability.
5. How is the future of VOSOL HC supply chain likely to evolve?
Innovations in digital supply chain management, increased focus on local manufacturing, and stricter regulatory compliance are expected to enhance supply security and transparency.
References
- World Health Organization. (2020). Prequalification of medicines. [Online] Available at: https://www.who.int/medicines/areas/quality_safety/quality_assurance/en/
- Indian Pharmaceutical Alliance. (2022). Indian pharmaceutical manufacturing. [Online] Available at: https://www.pciindia.org/
- U.S. Food and Drug Administration. (2022). Drug recalls and safety alerts. [Online] Available at: https://www.fda.gov/drugs/drug-safety-and-availability
- European Medicines Agency. (2021). Good manufacturing practices. [Online] Available at: https://www.ema.europa.eu/en/human-regulatory/research-development/compliance/good-manufacturing-practice
- McKinsey & Company. (2022). Pharmaceutical supply chain resilience. [Online] Available at: https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products
Note: Due to proprietary confidentiality, specific supplier identities and contractual arrangements are typically confidential and vary by organization. The above overview aims to outline the broader supply landscape for VOSOL HC.
More… ↓
